Gait Disorders in Patients With Cognitive Decline

Gait Disorders, Neurologic Clinical Trial

Official title:

Correlation Between Gait Disorders and Neuropsychological Profile in Patients With Alzheimer's Disease and Lewy Body Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03399591
• Other study ID #: 6963
• Status: Recruiting
• Start date: May 2, 2017
• Est. completion date: March 2019

Study information

• Verified date: January 2018
• Source: University Hospital, Strasbourg, France
• Contact: Jérémie PERISSE, MD
• Phone: 33 3 88 11 55 11
• Email: jeremie.perisse[@]chru-strasbourg.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The prevalence of neurodegenerative diseases will increase over the next decades driven by ageing population. It seems important to develop reliable, replicable and accessible diagnostic tools.

This is a prospective study whose objective is to study the spatio-temporal parameters of gait in patients with Alzheimer's and Lewy body diseases. 64 patients were included in this study. A comparison of the two pathologies was conducted, followed by an analysis based on four groups (mild, severe Alzheimer's disease, mild, severe Lewy body disease) and a study of the severity of the diseases. To study these parameters, we used the Gaitrite treadmill.

The analysis of spatio-temporal parameters of walking in Alzheimer's disease and Lewy body disease enables to identify discriminating variables between the two pathologies. The probability of suffering from an Alzheimer's disease decreases with the pace increase but increases with variations in length of the step, and with the rotation of the foot. While the probability of suffering from Lewy body disease increases with the pace, variations in the step duration, and the duration of double support.

These results are interesting but do not allow to establish a diagnostic score for these two diseases. The monitoring of the variations of these parameters at individual level would probably be more relevant and would enable to detect dual pathologies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: March 2019
• Est. primary completion date: March 2019
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Patient over 50

• Hospitalized patient in day hospital

• Patient with an etiological diagnosis of his cognitive disorder

• Patient having a neuropsychological assessment

• Patient able to walk without technical help

• Patient having agreed to participate in the study

Exclusion Criteria:

• Refusal to participate in the study

Related Conditions & MeSH terms

• Alzheimer Disease
• Disease
• Gait Disorders, Neurologic
• Lewy Body Disease
• Nervous System Diseases

Locations

Country	Name	City	State
France	Service de Gériatrie Hôpital de la Robertsau	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	walking test		1 hour after inclusion